Lineage Cell Therapeutics Inc

ASE:LCTX  
1.58
-0.07 (-4.24%)
4:51:30 PM EDT: $1.59 +0.01 (+0.63%)
Products, Strategic Combinations

Lineage Establishes Exclusive Worldwide Collaboration With Genentech

Published: 12/20/2021 11:37 GMT
Lineage Cell Therapeutics Inc (LCTX) - Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of Opregen® Rpe Cell Therapy for the Treatment of Ocular Disorders.
Lineage Cell Therapeutics Inc - Genentech Will Pay Lineage $50 Million Upfront.
Lineage Cell Therapeutics Inc - Eligible to Receive a Total of $670 Million in Upfront and Milestone Payments.
Lineage Cell Therapeutics - Co, Its Unit, Cell Cure Neurosciences, Entered Into Exclusive Collaboration, License Agreement With Roche and Genentech.